最新ニュース Moderna (NASDAQ:MRNA) 株価情報

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

Moderna Inc

Avian flu has continued to make headlines as cases extend beyond cattle and poultry; the flu has now affected cats and possibly horses. The flu has begun to affect <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">the American consumer</a> as egg prices soar.
The Latest On Bird Flu: A recent research study from the University of Glasgow found the virus is possibly spreading to horses in Mongolia and suggests the horses could spread the flu to humans. Professor Pablo Murcia, who led the research, <a href="https://news.sky.com/story/virus-most-likely-to-cause-next-pandemic-could-be-passed-to-humans-from-horses-study-finds-13271625" target="_blank" rel="noopener">told</a> SkyNews that knowledge of wildlife infections will help scientists monitor the virus.
Two cats in Los Angeles died from consuming raw milk that contained the virus, KTLA <a href="https://ktla.com/news/local-news/2-cats-die-from-possible-h5-bird-flu-in-los-angeles-county/">reports</a>. Cats can be exposed to the flu by eating infected birds or consuming unpasteurized milk from infected cattle. The Los Angeles County Department of Public Health noted that cats have reportedly been infected with the virus after drinking unpasteurized milk elsewhere.
Officials at the Wildlife World Zoo in Litchfield Park, Arizona, announced that five animals at the zoo died of avian flu, <a href="https://www.abc15.com/news/state/bird-flu-virus-hits-wildlife-world-zoo-park-implementing-safety-measures">according</a> to ABC15. The perished animals include a cheetah, a mountain lion, a swamphen, an Andean goose, and a kookaburra. A white tiger has also tested positive but is expected to make a full recovery.
In late November, a human in Canada who had been infected by the flu <a href="https://www.benzinga.com/general/health-care/24/11/42087908/mutated-bird-flu-case-in-california-puts-humans-at-increased-risk-so-which-companies-are-developing-vaccines">showed indications of mutation</a>. This is a sign the flu could spread more easily.
Bird Flu Vaccine: Biden Administration officials <a href="https://www.nbcnews.com/health/health-news/biden-administration-no-current-plans-authorize-bird-flu-vaccine-human-rcna183848">told</a> NBC News on Wednesday they have no plans to authorize a bird flu vaccine.
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">have reportedly worked</a> toward developing a bird flu vaccine.
A bird blu vaccine could be imperiled by an incoming presidential administration that is unreceptive to the scientific community. President-elect Donald Trump&#8216;s pick for secretary of Health and Human Services, vaccine skeptic Robert F. Kennedy Jr., has previously made several demonstrably false associations between vaccination and autism.
The New York Times <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">reported</a> on Friday that Kennedy&#8217;s lawyer asked the FDA to revoke approval of the polio vaccine. The polio vaccine has nearly eradicated polio in the United States. It has saved millions of lives and eliminated tens of millions of cases of paralysis. A May&nbsp;<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext" target="_blank" rel="noreferrer noopener">study</a>&nbsp;by Lanclet found that vaccines have saved 154 million lives throughout human history.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42484676/nvidia-amd-taiwan-semi-and-other-chip-stocks-gain-as-broadcoms-q4-sparks-sector-wide-surge">Nvidia, AMD, Taiwan Semi Gain As Broadcom&#8217;s Q4 Performance Sparks Sector-Wide Surge</a></li>
</ul>
Photo via Shutterstock.

Government

Health Care

Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is walking a tightrope this week, with its spot on the <a href="https://www.benzinga.com/topic/nasdaq-100">Nasdaq 100 Index</a> hanging in the balance. 
As the index reshuffles its lineup every December, the San Jose, California-based firm finds itself on the potential chopping block, alongside other underperforming stocks like Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Super Micro Computer benefitted from the surging demand for artificial intelligence infrastructure. At one point, it boasted a market cap of $67 billion. But a recent auditing scandal <a href="https://www.benzinga.com/24/12/42290180/cleared-of-fraud-but-super-micros-visibility-into-compliance-remains-low-says-analyst">caused its market cap to plummet</a>; it&#8217;s currently hovering at just below $20.4 billion.
Ernst &amp; Young flagged governance issues, sparking investor concerns, though a special committee later concluded these claims lacked sufficient evidence.
Super Micro Computer CEO Charles Liang expressed confidence at the Reuters NEXT conference, assuring investors that the company will meet its financial filing deadlines and remain on track for a February resolution.
Liang emphasized Super Micro&#8217;s robust relationships with major clients like xAI and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which could help stabilize its trajectory.
Read Also: <a href="https://www.benzinga.com/markets/24/12/42432508/smci-stock-drops-in-pre-market-despite-super-micro-ceos-assurance-against-delisting-whats-going-on">SMCI Stock Drops In Pre-Market Despite Super Micro CEO&#8217;s Assurance Against Delisting: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">Super Micro Computer Stock Chart Raises Questions</h2>
The technical charts, however, tell a mixed story. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png" alt="" class="wp-image-688046" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Super Micro Computer stock, at $37.95, is trading below its eight-day simple moving average (SMA) of $41.47, signaling short-term selling pressure. Yet, its 20-day SMA of $33.38 and 50-day SMA of $37.10 suggest medium-term strength, offering a glimmer of hope.
Still, the long-term picture looks bleak with a 200-day SMA at $67.21—a stark reminder of the stock's fall from grace.
<h2 class="wp-block-heading">JPMorgan's Take</h2>
Despite market skepticism, JPMorgan sees stability in Super Micro's order book and customer base. The firm highlighted "robust" orders and no signs of significant customer churn. 
With Nvidia's Blackwell product line gearing up for a major ramp in late fiscal 2025, the company&#8217;s role in AI infrastructure could prove pivotal.
<h2 class="wp-block-heading">The Verdict</h2>
While Super Micro clings to the hope of staying on the Nasdaq 100, Friday&#8217;s decision will likely hinge on its market value relative to stronger contenders like Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>). The clock is ticking for SMCI to prove it still belongs among tech&#8217;s elite.
Stay tuned — Friday the 13th could mark a turning point for this embattled AI infrastructure pioneer.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42444582/albertsons-puts-an-end-to-merger-deal-sues-kroger-following-court-ruling-we-believe-strongly-in-the-merits-of-our-case">Albertsons Puts End To Merger Deal, Sues Kroger Following Court Ruling: &#8216;We Believe Strongly In The Merits Of Our Case&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

Trading Ideas

BIIB

MSTR

NVDA

PLTR

SMCI

Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?

<a href="https://www.fda.gov/media/184301/download" title="https://www.fda.gov/media/184301/download">https://www.fda.gov/media/184301/download</a>

Biotech

General

FDA Highlights Safety Challenges And Development Needs For Pediatric RSV Vaccines Amid Historical Concerns And Recent mRNA Trial Pauses; Focus On Addressing Unmet Needs For Infants And Toddlers.

WIIM

Moderna shares are trading lower after B of A Securities reinstated an Underperform rating on the stock and announced a price target of $41.

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $220,016, and 3 are calls, amounting to $329,420.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.0 to $175.0 for Moderna over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $35.0 to $175.0, over the past month.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733845555_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.55</td>
<td>$10.5</td>
<td>$10.5</td>
<td>$55.00</td>
<td>$210.0K</td>
<td>1.1K</td>
<td align="right">202</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$18.8</td>
<td>$17.5</td>
<td>$18.14</td>
<td>$45.00</td>
<td>$90.7K</td>
<td>417</td>
<td align="right">51</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$5.2</td>
<td>$5.05</td>
<td>$5.15</td>
<td>$35.00</td>
<td>$69.5K</td>
<td>520</td>
<td align="right">139</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.05</td>
<td>$8.32</td>
<td>$45.00</td>
<td>$41.5K</td>
<td>1.6K</td>
<td align="right">62</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.01</td>
<td>$1.94</td>
<td>$1.94</td>
<td>$44.00</td>
<td>$30.8K</td>
<td>482</td>
<td align="right">33</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>With a volume of 2,515,833, the price of MRNA is down -3.57% at $44.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 72 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $50.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wolfe Research has revised its rating downward to Underperform, adjusting the price target to $40. 
&#x2A; An analyst from HSBC upgraded its action to Buy with a price target of $58. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $41. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Overweight with a new price target of $69. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $45. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Moderna

In the last three months, 19 analysts have published ratings on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.63, with a high estimate of $139.00 and a low estimate of $40.00. A decline of 28.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1733842812_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Moderna is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$59.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Courtney Breen</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$139.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Moderna's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>Delving into Moderna's Background</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Financial Insights: Moderna</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Moderna's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 3.81%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.7%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Moderna's ROE excels beyond industry benchmarks, reaching 0.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Moderna's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Moderna Through The Eyes Of 19 Analysts

B of A Securities analyst Tim Anderson reinstates Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underperform and announces $41 price target.

Price Target

Initiation

B of A Securities Reinstates Underperform on Moderna, Announces $41 Price Target

<a href="https://www.axios.com/2024/12/05/trump-rfk-jr-pfizer-lilly">https://www.axios.com/2024/12/05/trump-rfk-jr-pfizer-lilly</a>
&nbsp;
<a href="https://www.axios.com/politics-policy/donald-trump">President-elect Trump</a> hosted the chief executives of Pfizer, Eli Lilly and PhRMA Wednesday night at Mar-a-Lago, where they discussed how the public and private sectors can collaborate on finding cures for cancer, among other topics, Axios has learned.
Why it matters: The patio dinner is a potential indication that Trump's administration will see the pharmaceutical industry as a partner — not just an adversary — for parts of its <a href="https://www.axios.com/2024/11/14/maha-movement-federal-health-agencies">"Make America Healthy Again"</a> agenda.
<ul>
<li>There's been much speculation about how Trump's team will deal with the industry, given Trump's<a href="https://www.axios.com/2023/06/30/pharma-another-term-without-friend-white-house"> tough talk</a> during the campaign and his pick of vaccine skeptic Robert F. Kennedy Jr. as Health and Human Services secretary.</li>
<li>Last month, <a href="https://www.axios.com/2024/11/14/vaccine-stocks-fall-trump-rfk-health-secretary-hhs">drugmakers' share prices</a> dropped after Trump announced the nomination of Kennedy, who was at Wednesday's dinner along with Dr. Mehmet Oz, Trump's pick to run the Centers for Medicare &amp; Medicaid Services.</li>
</ul>
Pfizer CEO Albert Bourla, Lilly CEO David Ricks were at the dinner. Steve Ubl, CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) represented the industry at the table. Trump's incoming chief of staff, Susie Wiles, also attended.
Zoom out: In his first term, Trump worked in concert with the private sector as part of <a href="https://www.axios.com/2020/08/11/moderna-vaccine-coronavirus-trump">Operation Warp Speed</a> to accelerate the development and delivery of COVID-19 vaccines and therapeutics.
<ul>
<li>But drugmakers are still reeling from Democrats' new law allowing <a href="https://www.axios.com/2023/01/11/medicare-drug-price-negotiation-hhs-process">Medicare to negotiate the price of drugs</a>. During the presidential campaign, both President <a href="https://www.axios.com/politics-policy/joe-biden">Biden</a> and <a href="https://www.axios.com/politics-policy/donald-trump">Trump</a> promised even harsher crackdowns on the industry.</li>
</ul>
&nbsp;
Zoom in: The meeting at Mar-a-Lago included a pre-dinner reception and lasted nearly three hours.
<ul>
<li>As dinner was winding down, Trump entertained his guests by playing D.J. with his <a href="https://www.axios.com/2024/04/04/donald-trump-news-mar-a-lago">Spotify playlist</a>.</li>
</ul>
Go deeper: Biden made <a href="https://www.axios.com/2022/02/02/biden-relaunch-cancer-death-rate-moonshot">finding a cure for cancer</a> a central plank of his health care agenda, reviving the "moon shot" research program he spearheaded as vice president.
What they're saying: Trump's transition team and a Lilly representative did not immediately respond to a request for comment. Spokespeople for Pfizer PhRMA declined to comment.

"Scoop: Trump, RFK Jr. Dine With Pfizer And Lilly Execs" - Axios

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

ARWR

CPRT

ESTC

EXAS

RIVN

RKLB

SNAP

SRPT

ULTA

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $1,196,435 and 2, calls, for a total amount of $1,384,310.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $105.0 for Moderna, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3135.88 with a total volume of 4,381.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $105.0 over the last 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732895188_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.05</td>
<td>$4.8</td>
<td>$4.85</td>
<td>$50.00</td>
<td>$1.3M</td>
<td>1.5K</td>
<td>2.7K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.5</td>
<td>$4.95</td>
<td>$5.25</td>
<td>$30.00</td>
<td>$446.2K</td>
<td>1.4K</td>
<td>852</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.25</td>
<td>$11.4</td>
<td>$13.25</td>
<td>$55.00</td>
<td>$331.2K</td>
<td>4.7K</td>
<td>10</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.05</td>
<td>$11.85</td>
<td>$11.85</td>
<td>$50.00</td>
<td>$141.0K</td>
<td>4.0K</td>
<td>120</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$11.2</td>
<td>$11.15</td>
<td>$11.2</td>
<td>$50.00</td>
<td>$76.1K</td>
<td>112</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>Currently trading with a volume of 1,119,525, the MRNA's price is up by 0.14%, now at $43.45. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Moderna's Options: A Look at What the Big Money is Thinking

Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's <a href="https://www.benzinga.com/general/health-care/24/11/42087908/mutated-bird-flu-case-in-california-puts-humans-at-increased-risk-so-which-companies-are-developing-vaccines">department of public health.&nbsp;</a>
The Details: The virus was found during testing of a batch of whole raw milk from Raw Farm in Fresno county. The company has issued a voluntary recall of the batch, which has a &#8220;best by date&#8221; of Nov. 27. 
"Out of an abundance of caution, and due to the ongoing spread of bird flu in dairy cows, poultry, and sporadic human cases, consumers should not consume any of the affected raw milk," the California Department of Public Health said in <a href="https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-039.aspx">a Sunday statement.&nbsp;</a>
Read More: <a href="https://www.benzinga.com/24/11/42194570/starbucks-employee-systems-down-after-software-provider-suffers-ransomware-attack">Starbucks&#8217; Employee Systems Down After Software Provider Suffers Ransomware Attack</a>
California reported 29 confirmed human cases of bird flu since early October, with 28 of the cases resulting from direct contact with infected dairy cows. No person-to-person spread of bird flu has been detected in California or the U.S., according to the state's public health department.&nbsp;
Vaccine Efforts: As concern about the possible spread of bird flu grows, the U.S. government is increasing its efforts to develop a stockpile of vaccines for the disease.&nbsp;
Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.&nbsp;&nbsp;
In October, the Department of Health and Human Services granted GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Australian firm CSL Limited $72 million to <a href="https://www.benzinga.com/general/biotech/24/10/41188886/gsk-sanofi-and-csl-secure-us-government-fund-to-boost-bird-flu-vaccine-production-report">more than double</a> the U.S. supply of bird flu vaccines.&nbsp;
According to the CDC, 55 total cases have been reported in the 2024 bird flu outbreak in the U.S. The CDC said that it is monitoring <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">the bird flu situation </a>carefully and working with states to monitor people with animal exposures, though the current public health risk is low.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Pexels

Bird Flu Found In Raw Milk Leads To Recall In California

Moderna shares are trading lower after JP Morgan maintained an Underweight rating on the stock and lowered its price target from $59 to $45.

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underweight and lowers the price target from $59 to $45.

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $45

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 2.89% on an annualized basis producing an average annual return of 16.57%. Currently, Moderna has a market capitalization of $16.88 billion. 
Buying $100 In MRNA: If an investor had bought $100 of MRNA stock 5 years ago, it would be worth $215.28 today based on a price of $43.87 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732566659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.
Shares of BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) rose sharply during Monday's session after the company announced that the FDA approved Attruby to <a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market">treat adults with ATTR-CM.</a>
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.
BridgeBio Pharma shares jumped 22.3% to $28.64 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares jumped 69% to $2.9289 after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) gained 27.2% to $38.03. Scholar Rock Holding recently reported worse-than-expected third-quarter EPS results.</li>
<li>D-Wave Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) surged 26.3% to $3.6800 after AWS announced Quantum Embark program.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) gained 23.3% to $6.15.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 19% to $7.26 after AWS announced Quantum Embark program.</li>
<li>Eastman Kodak Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) surged 17.4% to $6.18.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 16.6% to $38.36.</li>
<li>Eve Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) gained 16.6% to $3.9062.</li>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares climbed 15.5% to $35.49 after the company reported better-than-expected third-quarter EPS and sales and raised its 2024 guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) surged 14.6% to $6.92.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) rose 13.5% to $28.77.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 11.3% to $9.52.</li>
<li>Clarivate Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) rose 8.7% to $5.70.</li>
<li>Flagstar Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) gained 7.1% to $12.52.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) climbed 6.8% to $92.82. Five Below will release its financial results for the third quarter of fiscal 2024 after the closing bell on Wednesday, Dec. 4.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) climbed 6.3% to $43.74.</li>
<li>Jones Lang LaSalle Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) gained 6.1% to $279.28. Wolfe Research analyst Andrew Rosivach upgraded Jones Lang LaSalle from Peer Perform to Outperform and announced a $353 price target.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose 6% to $114.49 after Wedbush upgraded the stock from Neutral to Outperform and announced a $135 price target.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Intraday Update

ACHR

BBIO

BBWI

CLVT

EVEX

FIVE

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

KODK

QBTS

QUBT

RGTI

SRRK

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 3.25% since its last report. The company recently reported that it has 34.38 million shares sold short, which is 11.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732301111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 4.72%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Moderna's Recent Short Interest

<a href="https://qz.com/fda-peter-marks-rjk-vaccines-1851705107">https://qz.com/fda-peter-marks-rjk-vaccines-1851705107</a>
The U.S. Food and Drug Administration's (FDA) head of vaccine safety says that President-elect Donald Trump's embrace of vaccine skeptics could be an opportunity for the science community to teach the public about the value of these life-saving drugs. However, if these efforts fail it could lead to "natural consequences."
The FDA's Peter Marks made the remarks Thursday at the Jefferies London Healthcare Conference. Marks is the current director of the Center for Biologics Evaluation and Research (CBER) at the FDA. The center ensures the safety and effectiveness of biological products, including vaccines.
Marks said now is the chance for scientists to make the case for vaccines, as Trump has named noted anti-vaccine crusader Robert F. Kennedy Jr. as his pick to be the next Secretary of Health and Human Services.
Bloomberg is also reporting that Trump is likely to pick surgeon and public health researcher Marty Makary as the next head of the FDA. Previously, Makary has criticized the agency's approval of COVID-19 booster vaccines. Additionally, he has written several op-eds on the pandemic including one claiming that the U.S. would achieve <a href="https://www.wsj.com/articles/well-have-herd-immunity-by-april-11613669731">herd immunity by April 2021 </a>and a more recent one arguing that vaccines shouldn't be <a href="https://www.wsj.com/articles/biden-waves-another-covid-shot-through-fda-human-outcomes-data-195731c0">recommended universally</a> for lower-risk patients.
Marks said that if public health officials fail to make the case for vaccines there will be consequences.
"If that doesn't work, and everything runs wild in the opposite direction, just as your kids learn natural consequences — if you put your hand on a hot oven, you will get burned, et cetera, that kind of thing — the American public will learn the natural consequences of what happens if vaccination rates fall too far, because we will start to see measles, polio, things that we should never see in a well-developed country, come back," said Marks, who was speaking virtually at the conference, <a href="https://www.statnews.com/2024/11/21/peter-marks-fda-rfk-jr-vaccine-safety/">STAT reported</a>.
Marks said he expects a vigorous debate on COVID-19 vaccines and pediatric vaccines but hopes a "degree of moderation will prevail" on the topic of vaccines overall.

BNTX

NVAX

Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA vaccine official says RFK Jr. nomination is a chance for scientist to make the case for vaccines"

<a href="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html" title="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html">https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html</a>

U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks

A child in Alameda County, California is the latest case of <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">bird flu in the U.S.</a> 
According to the <a href="https://www.latimes.com/environment/story/2024-11-19/alameda-county-child-believed-to-be-latest-case-of-bird-flu-source-unknown">Los Angeles Times</a>, the total case count in the U.S. stands at 54. Thirty-one cases are attributed to the dairy industry and 21 to the poultry industry. Two of the case&#8217;s causes are unknown.
Companies are <a href="https://www.benzinga.com/general/biotech/23/03/31416800/large-vaccine-players-including-gsk-moderna-prepare-for-bird-flu-vaccine-just-in-case">racing to develop vaccines</a>, but observers worry that the incoming Trump administration&#8217;s selection of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services could put a potential treatment in the crosshairs.
Health researchers are exploring the idea that the virus was spread via wild birds. The California child&#8217;s genetic sequencing has not been released; it is therefore unclear if it is of wild bird or dairy origins.
Meanwhile, a teenager in Canada who was hospitalized with the bird flu possibly showed signs of mutation, the Guardian <a href="https://www.theguardian.com/world/2024/nov/19/bird-flu-cases-mutation-canada">reports</a>.
Experts are reportedly concerned that a mutation in the virus would make it easier to spread, making the odds of a widespread outbreak more likely.
Vaccine Efforts: Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) are currently developing an <a href="https://www.benzinga.com/general/health-care/24/11/41949697/bird-flu-puts-teen-in-critical-condition-as-canada-reports-first-human-case-what-you-need-to-know">mRNA bird flu vaccine</a> using similar technology to the companies' COVID-19 vaccines.
The U.S. government has <a href="https://www.benzinga.com/general/biotech/24/10/41188886/gsk-sanofi-and-csl-secure-us-government-fund-to-boost-bird-flu-vaccine-production-report">also awarded grants</a> to European pharmaceutical giants GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Regulatory Question Marks: Kennedy, Donald Trump&#8217;s pick to lead the HHS, is widely known as <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">a vaccine-skeptic</a>. While the Kennedy family heir says he will not &#8220;take away anybody's vaccines,&#8221; his ultimate regulatory intentions are unclear. A bird flu vaccine could face additional hurdles in a Trump administration.
In the past, Kennedy has falsely associated <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">vaccinations with autism</a> in children, a claim that has been thoroughly disproven in the scientific field. A May Lancet <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">study</a> found that vaccines have saved 154 million lives throughout human history. They have effectively treated polio, measles, pertussis, and other diseases.
Kennedy may face a tough confirmation vote in the Republican-controlled Senate given his pro-choice abortion stances. He has, however, found a unique <a href="https://x.com/jaredpolis/status/1857173250586911189">ally</a> in Colorado Governor Jared Polis, a Democrat.
Pfizer, Moderna and other vaccine manufacturers&#8217; stock fell on the news of Kennedy&#8217;s selection.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/events/24/11/42073346/exclusive-retail-investors-are-taking-on-more-risk-and-finding-success-is-crypto-acting-as-a-gateway-trade">EXCLUSIVE: Retail Investors Are Taking On More Risk And Finding Success — Is Crypto Acting As A &#8216;Gateway Trade?&#8217;</a></li>
</ul>
Image: Shutterstock

Equities

Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 37 trades.
If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 59% with bearish.
From the overall spotted trades, 19 are puts, for a total amount of $1,152,330 and 18, calls, for a total amount of $1,026,287.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $300.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $30.0 to $300.0, over the past month.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732047342_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$40.00</td>
<td>$169.5K</td>
<td>1.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$34.95</td>
<td>$33.8</td>
<td>$33.8</td>
<td>$70.00</td>
<td>$168.9K</td>
<td>1.0K</td>
<td>50</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$24.05</td>
<td>$24.0</td>
<td>$24.05</td>
<td>$60.00</td>
<td>$137.0K</td>
<td>1.1K</td>
<td>59</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.21</td>
<td>$45.00</td>
<td>$124.0K</td>
<td>733</td>
<td>389</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$40.00</td>
<td>$113.1K</td>
<td>1.3K</td>
<td>344</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Moderna</h3>
<ul>
<li>Trading volume stands at 5,807,278, with MRNA's price down by -4.83%, positioned at $37.6.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here's an updated look at the top 10 worst performing large-caps, along with their one-year price returns.

Large-Cap Stocks In Trouble - Sunday, Dec. 8

How is QQQ stock faring? The Invesco QQQ ETF is up 1.2% in the past five days and has risen about 29.12% year-to-date. &nbsp; According to TipRanks...

QQQ ETF Update, 12/9/2024

Tax-Loss Stocks To Sell Before Everyone Else Does

How is VOO stock faring? The Vanguard S&P 500 ETF&nbsp;is down 0.53% in the past five days but has risen 32.78% over the past year. According to Ti...

VOO ETF Update, 12/10/2024

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

eBay downgraded, GM upgraded: Wall Street's top analyst calls

BofA restarts coverage of 11 large-cap biopharmas

Evercore ISI downgraded Carisma Therapeutics (CARM) to In Line from Outperform with a price target of 70c, down from $4. With its second major pipe...

Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI

How is QQQ stock faring? The Invesco QQQ ETF is up 0.89% in the past 5 days and has risen about 31.5% over the past year.   According to TipRanks' ...

QQQ ETF Update, 12/12/2024

MicroStrategy ($MSTR) is on track to make a big leap this month, with expectations it will join the Nasdaq 100 on December 23. According to Bloombe...

MicroStrategy Set to Leap into the Nasdaq 100

Carisma downgraded by Baird over lack of near-term catalysts

ABBV

ABNB

AMGN

ARRY

BKNG

BMWKY

CARM

CTAS

DLTR

DXCM

EBAY

ENPH

FSLR

GILD

GRMN

INTC

MBGAF

MBGYY

MCHP

NCLH

NFLX

OSCR

PAYC

PINS

QRVO

REGN

SEDG

STLA

TMUS

TSLA

VLKAF

VLKPF

VSCO

VWAGY

VWAPY

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Events

Moderna to Present at Upcoming Conferences in December 2024

Legal

DexCom, Orthofix, Spire Global, and Moderna Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Comments

Moderna

ニュース

最新ニュース Moderna (NASDAQ:MRNA) 株価情報

月曜日, 7 01, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル